ID   MFUM-BrTNBC-1
AC   CVCL_B5N7
SY   Medical Faculty University of Maribor-Breast Triple Negative Breast Cancer-1
DR   Wikidata; Q112129315
RX   PubMed=31749235;
RX   PubMed=35011679;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian; Slovenian.
CC   Characteristics: Shown by ICC and PCR to be ER-negative, PR-negative and ERBB2-negative (PubMed=35011679).
CC   Doubling time: 80 hours (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 393; AKT3; Simple; p.Lys294Ter (c.880A>T); Zygosity=Heterozygous (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Tyr2037Ter (c.6111C>G); Zygosity=Heterozygous (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly32Arg (c.94G>C); ClinVar=VCV001690925; Zygosity=Heterozygous (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 7993; NRBP1; Simple; p.Lys217Ter (c.649A>T); Zygosity=Heterozygous (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=35011679).
CC   Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gln829Ter (c.2485C>T); Zygosity=Heterozygous (PubMed=35011679).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): PubMed=35011679
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13,14
ST   D16S539: 11,12
ST   D18S51: 12,16
ST   D19S433: 13,14
ST   D21S11: 28,31.2
ST   D2S1338: 22,24
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 12,14
ST   FGA: 23
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 29-06-23; Version: 5
//
RX   PubMed=31749235; DOI=10.1111/tbj.13695;
RA   Skok K., Gradisnik L., Celesnik H., Potocnik U., Kavalar R., Takac I.,
RA   Maver U.;
RT   "Isolation and characterization of the first Slovenian human
RT   triple-negative breast cancer cell line.";
RL   Breast J. 26:328-330(2020).
//
RX   PubMed=35011679; DOI=10.3390/cells11010117;
RA   Skok K., Gradisnik L., Celesnik H., Milojevic M., Potocnik U.,
RA   Jezernik G., Gorenjak M., Sobocan M., Takac I., Kavalar R., Maver U.;
RT   "MFUM-BrTNBC-1, a newly established patient-derived triple-negative
RT   breast cancer cell line: molecular characterisation, genetic
RT   stability, and comprehensive comparison with commercial breast cancer
RT   cell lines.";
RL   Cells 11:117.1-117.23(2022).
//